Sen. John Boozman Sells Off Johnson & Johnson (NYSE:JNJ) Shares

Senator John Boozman (Republican-Arkansas) recently sold shares of Johnson & Johnson (NYSE:JNJ). In a filing disclosed on September 11th, the Senator disclosed that they had sold between $1,001 and $15,000 in Johnson & Johnson stock on August 20th.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of iShares Core S&P 500 ETF (NYSEARCA:IVV) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of Otis Worldwide (NYSE:OTIS) on 8/27/2026.
• Purchased $1,001 – $15,000 in shares of State Street SPDR Portfolio S&P 500 ETF (NYSEARCA:SPYM) on 8/20/2026.
• Purchased $1,001 – $15,000 in shares of iShares Core S&P Small-Cap ETF (NYSEARCA:IJR) on 8/19/2026.
• Purchased $1,001 – $15,000 in shares of Avantis U.S. Small Cap Value ETF (NYSEARCA:AVUV) on 8/19/2026.
• Purchased $1,001 – $15,000 in shares of First Solar (NASDAQ:FSLR) on 8/13/2026.
• Sold $1,001 – $15,000 in shares of Constellation Energy (NASDAQ:CEG) on 8/13/2026.
• Sold $1,001 – $15,000 in shares of Cboe Global Markets (BATS:CBOE) on 7/31/2026.
• Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of State Street SPDR Portfolio S&P 500 ETF (NYSEARCA:SPYM) on 7/23/2026.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded down $0.44 during mid-day trading on Friday, hitting $265.91. 4,701,138 shares of the stock were exchanged, compared to its average volume of 6,021,000. Johnson & Johnson has a 12 month low of $173.33 and a 12 month high of $281.07. The company has a 50-day simple moving average of $263.03 and a 200 day simple moving average of $245.93. The company has a market capitalization of $640.82 billion, a P/E ratio of 30.81, a P/E/G ratio of 2.54 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.81 and a current ratio of 1.09.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, July 15th. The company reported $2.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.84 by $0.06. The company had revenue of $25.31 billion during the quarter, compared to analyst estimates of $25.06 billion. Johnson & Johnson had a return on equity of 32.42% and a net margin of 21.48%.Johnson & Johnson’s quarterly revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the company posted $2.77 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.600-11.750 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.61 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Tuesday, September 8th. Shareholders of record on Tuesday, August 25th were given a dividend of $1.34 per share. The ex-dividend date of this dividend was Tuesday, August 25th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 62.11%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson received CE Marking in Europe for ACUVUE OASYS MAX 2-Week reusable contact lenses, expanding its Vision Care product portfolio. The approval could support future sales, though its immediate financial impact is likely limited. Johnson & Johnson Receives CE Marking for ACUVUE OASYS MAX Reusable Contact Lenses
• Positive Sentiment: China approved Icotyde, J&J’s once-daily oral treatment for moderate-to-severe plaque psoriasis. The drug gives the company access to a large patient population and may attract patients who prefer an oral therapy to injectable alternatives, creating a potential growth catalyst. Could Icotyde Become Johnson & Johnson’s Next Blockbuster in China?
• Positive Sentiment: Investor-focused coverage continues to highlight J&J as a Dividend Aristocrat that has maintained and increased its payout through past crises, supporting its appeal as a defensive income stock. The company also recently exceeded quarterly earnings and revenue expectations. 3 Top Dividend Aristocrats To Own Near All-Time Highs
• Neutral Sentiment: J&J is trading near its 12-month high after a strong advance, indicating sustained market confidence but also leaving less room for upside without additional earnings growth.
• Negative Sentiment: Analysts are questioning whether the rally is losing momentum. With shares valued at roughly 31 times earnings, profit-taking or valuation concerns could weigh on the stock despite the company’s defensive qualities and new growth opportunities. JNJ Stock: Is the Rally Running Out of Steam?

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Blueline Advisors LLC bought a new position in shares of Johnson & Johnson in the fourth quarter worth $25,000. Outlook Capital Management LLC bought a new stake in Johnson & Johnson during the second quarter valued at $28,000. Semmax Financial Advisors Inc. grew its position in Johnson & Johnson by 55.0% during the second quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares in the last quarter. E Fund Management Hong Kong Co. Ltd. increased its stake in Johnson & Johnson by 946.7% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 157 shares of the company’s stock worth $32,000 after acquiring an additional 142 shares during the last quarter. Finally, MidAtlantic Capital Management Inc. bought a new position in Johnson & Johnson in the 4th quarter worth about $37,000. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president owned 194,451 shares of the company’s stock, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Vanessa Broadhurst sold 23,054 shares of the stock in a transaction on Monday, July 20th. The stock was sold at an average price of $251.27, for a total transaction of $5,792,778.58. Following the completion of the transaction, the executive vice president directly owned 23,003 shares in the company, valued at $5,779,963.81. The trade was a 50.06% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 87,569 shares of company stock worth $23,064,544. Insiders own 0.16% of the company’s stock.

Analysts Set New Price Targets

A number of research firms recently issued reports on JNJ. Argus set a $300.00 price objective on shares of Johnson & Johnson in a report on Wednesday, July 29th. TD Cowen boosted their target price on shares of Johnson & Johnson from $250.00 to $300.00 and gave the company a “buy” rating in a research note on Monday, July 13th. Wells Fargo & Company increased their target price on shares of Johnson & Johnson from $272.00 to $282.00 and gave the company an “overweight” rating in a research report on Monday, August 3rd. Stifel Nicolaus set a $260.00 price target on shares of Johnson & Johnson in a report on Wednesday, July 15th. Finally, Freedom Capital upgraded Johnson & Johnson from a “hold” rating to a “strong-buy” rating in a research note on Thursday, July 16th. One equities research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and six have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $274.13.

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

About Johnson & Johnson

Johnson & Johnson (NYSE: JNJ) is a global healthcare company that develops, manufactures and markets pharmaceutical and medical device products. Founded in 1886 and headquartered in New Brunswick, New Jersey, the company serves patients, healthcare professionals and institutions in markets around the world.

Johnson & Johnson operates through two primary business segments: Innovative Medicine and MedTech. Innovative Medicine focuses on prescription treatments in areas including immunology, oncology, neuroscience, cardiovascular and metabolic disease, infectious diseases, and pulmonary hypertension.